Danaher Co. (NYSE:DHR) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Danaher Co. (NYSE:DHR) have been assigned a consensus rating of “Moderate Buy” from the seventeen research firms that are currently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $276.88.

A number of research firms have recently issued reports on DHR. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and lifted their price objective for the company from $250.00 to $280.00 in a report on Wednesday, April 17th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Stifel Nicolaus boosted their price target on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Barclays raised their target price on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Finally, Royal Bank of Canada increased their price target on shares of Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th.

Insider Buying and Selling at Danaher

In related news, CEO Rainer Blair sold 19,085 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $255.00, for a total value of $4,866,675.00. Following the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $29,578,725. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Rainer Blair sold 19,085 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $255.00, for a total transaction of $4,866,675.00. Following the completion of the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $29,578,725. The disclosure for this sale can be found here. In the last quarter, insiders have sold 113,174 shares of company stock worth $29,775,644. Insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Cary Street Partners Investment Advisory LLC grew its holdings in Danaher by 20.2% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after buying an additional 1,533 shares in the last quarter. Cercano Management LLC grew its position in shares of Danaher by 11.4% during the 4th quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock valued at $46,862,000 after purchasing an additional 20,715 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Danaher by 48.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after purchasing an additional 96,395 shares during the period. Donaldson Capital Management LLC boosted its stake in Danaher by 5.8% during the first quarter. Donaldson Capital Management LLC now owns 1,469 shares of the conglomerate’s stock valued at $367,000 after buying an additional 80 shares during the period. Finally, Caden Capital Partners LP grew its position in Danaher by 12.4% during the fourth quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after buying an additional 15,313 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 2.7 %

Shares of Danaher stock opened at $269.35 on Thursday. The company’s fifty day moving average price is $256.29 and its two-hundred day moving average price is $251.12. The firm has a market capitalization of $194.53 billion, a PE ratio of 45.70, a price-to-earnings-growth ratio of 4.62 and a beta of 0.83. Danaher has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the business posted $2.05 earnings per share. Danaher’s revenue for the quarter was down 2.9% compared to the same quarter last year. On average, analysts expect that Danaher will post 7.59 EPS for the current year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.